DDrare: Database of Drug Development for Rare Diseases

94. 原発性硬化性胆管炎
［臨床試験数：134，薬物数：105（DrugBank：37），標的遺伝子数：18，標的パスウェイ数：131］

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-CSar; 3108006977; ACETYLCYSTEINE; ACIDO OBETICOLICO; ATRA; AZT; Acetylcysteine; All-trans retinoic acid; Azathioprine; BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée; BEZAFIBRATE; BTT1023; BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product; Befizal; Bezafibrate; Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy; Bezalip; Budesonide; C10AB02; CILO; CM-101; Calcium; Capecitabine; Cenicriviroc; Cenicriviroc 150 mg; Cilofexor; Cis-4-Hydroxy-L-Proline; Cladribine; Curcumin; DHA; DUR-928; Docosahexaenoic Acid (DHA); Docosahexaenoic acid; Engineered recombinant human FGF19; Entyvio; Erlotinib; Erlotinib (Tarceva); FLUIMUCIL*20CPR EFF 600MG; Fecal Microbiota Transplantation; Fenofibrate; Fluimucil; GS-6624; GS-9674; Gluten-free diet; HTD1801; Humanised IgG1 monoclonal antibody against human eotaxin-2; Hymecromone; ICG; INT-747, OCA; LUM001; MBX-8025; MLN0002; Metronidazole; Minocycline; Mitomycin; Mitomycin C; Mizoribine; NGM282; NorUDCA; NorUrsodeoxycholic Acid; NorUrsodeoxycholic acid; Normal saline; Norursodeoxycholic acid; OCA; OCA 1,5 mg; OCA 5 mg; Oral Vancomycin; Oral all-trans retinoic acid (ATRA); Orbcel-C; PLN-74809; Phenylbutyrate; Probiotics; Procedure: Liver transplantation; Procedure: Pre liver transplantation laparoscopic hand assisted staging; Proline; Radiation: 45 Gy external radiations; Radiation: Endoluminal bile duct Brachytherapy; Rec-h-FGF19; Retinoic acid; Rituximab; SELADELPAR; Seladelpar; Simtuzimab; Simtuzumab; Simvastatin; Simvastatin 40mg; Sulfasalazine; TBC; Thalidomide; UCMSC; UDCA; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ursodeoxycholic acid (UDCA); Ursofalk; Ursolic acid; VEDOLIZUMAB; Vancomycin; Vedolizumab; Vedolizumab IV; Vidofludimus; Vidofludimus calcium; Volixibat; Xifaxan; [18F]FP-R01-MG-F2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000021411	2016/04/01	01/04/2016	clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis	clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis - clinical efficacy of oral administration of metronidazole in the treatment of PSC	primary sclerosing cholangitis	Patients take metronidazole 250mg orally three times day for 3 weeks.	Keio University, School of Medicine	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	20	Not applicable	Japan
2	NCT03069976 (ClinicalTrials.gov)	January 2016	28/2/2017	Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children	Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Modification With Antibiotics in Children	Primary Sclerosing Cholangitis;Autoimmune Hepatitis;Overlap Syndrome	Drug: Metronidazole	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	NULL	Recruiting	3 Years	25 Years	All	20	N/A	Belgium
3	NCT01085760 (ClinicalTrials.gov)	February 2010	10/3/2010	A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis	A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis	Primary Sclerosing Cholangitis	Drug: Vancomycin;Drug: Metronidazole	Mayo Clinic	PSC Partners Seeking a Cure Foundation	Completed	18 Years	75 Years	All	35	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000021411

2016/04/01

01/04/2016

clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis

clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis - clinical efficacy of oral administration of metronidazole in the treatment of PSC

primary sclerosing cholangitis

Patients take metronidazole 250mg orally three times day for 3 weeks.

Keio University, School of Medicine

NULL

Complete: follow-up complete

16years-old

Not applicable

Male and Female

Not applicable

Japan

NCT03069976
(ClinicalTrials.gov)

January 2016

28/2/2017

Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children

Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Modification With Antibiotics in Children

Primary Sclerosing Cholangitis;Autoimmune Hepatitis;Overlap Syndrome

Drug: Metronidazole

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NULL

Recruiting

3 Years

25 Years

All

N/A

Belgium

NCT01085760
(ClinicalTrials.gov)

February 2010

10/3/2010

A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

Drug: Vancomycin;Drug: Metronidazole

Mayo Clinic

PSC Partners Seeking a Cure Foundation

Completed

18 Years

75 Years

All

Phase 1

United States